Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 19,2024
Medicilon Boston's Second R&D Center Grandly Sets Sail
On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets.
More
Medicilon Boston's Second R&D Center Grandly Sets Sail
Oct 08,2024
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
More
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Sep 13,2024
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).
More
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Sep 13,2024
Medicilon Non-tumor Pharmacology Service Platform
Medicilon boasts 260+ evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases.
More
Medicilon Non-tumor Pharmacology Service Platform
Aug 29,2024
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.
More
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
Aug 06,2024
Medicilon's Antibody Technology Targeting Nectin-4 has been Awarded a National Invention Patent
Recently, Medicilon has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"!
More
Medicilon's Antibody Technology Targeting Nectin-4 has been Awarded a National Invention Patent
Jul 31,2024
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.
More
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Jul 26,2024
2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang
From July 3 to 6, 2024, 2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang, Jiangxi.
More
2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang
Jul 26,2024
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
On July 17, Dr. Yaoyu Chen, Co-founder of Allorion Therapeutics (Allorion), and Dr. Jiaqi Liang, Head of Biology, visited Medicilon's Chuansha campus in Shanghai to present the "Excellent Service Award" to Medicilon's pharmacology department.
More
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
Jul 22,2024
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
More
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
Jul 22,2024
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
More
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Jul 22,2024
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
More
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->